We are live on ! Find out more
PTCT icon

PTC Therapeutics
PTCT

99 hedge funds and large institutions have $1.07B invested in PTC Therapeutics in 2014 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 23 increasing their positions, 26 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

83% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 18

78% more capital invested

Capital invested by funds: $601M → $1.07B (+$471M)

18% more funds holding

Funds holding: 84 → 99 (+15)

12% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 26

Holders
99
Holders Change
+15
Holders Change %
+17.86%
% of All Funds
2.87%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
33
Increased
23
Reduced
26
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$25.6M
2
TAM
Tocqueville Asset Management
New York
+$9.37M
3
UBS AM
UBS AM
Illinois
+$8.56M
4
Citadel Advisors
Citadel Advisors
Florida
+$7.46M
5
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$7.28M

Top Sellers

Rank Fund Capital Flow
1
CS
Credit Suisse
Switzerland
-$22.2M
2
SAM
Sectoral Asset Management
Quebec, Canada
-$7.16M
3
NI
Numeric Investors
Massachusetts
-$6.79M
4
O
OrbiMed
New York
-$4.66M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$3.96M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
101
OrbiMed
New York
– -$4.66M -178,100 Closed
PC
102
Pier Capital
Connecticut
– -$3.54M -135,445 Closed
Balyasny Asset Management
103
Balyasny Asset Management
Illinois
– -$1.09M -41,820 Closed
ARC
104
Absolute Return Capital
Massachusetts
– -$839K -32,080 Closed
D.E. Shaw & Co
105
D.E. Shaw & Co
New York
– -$635K -24,292 Closed
Renaissance Technologies
106
Renaissance Technologies
New York
– -$565K -21,600 Closed
Jane Street
107
Jane Street
New York
– -$469K -17,947 Closed
BACM
108
Blue Arrow Capital Management
New York
– -$353K -13,500 Closed
Susquehanna International Group
109
Susquehanna International Group
Pennsylvania
– -$279K -10,666 Closed
Bank of Montreal
110
Bank of Montreal
Ontario, Canada
– -$269K -10,290 Closed
N
111
Nuveen
North Carolina
– -$317K -8,758 Closed
EWM
112
Evercore Wealth Management
New York
– -$78K -3,000 Closed
VFA
113
Virtus Fund Advisers
Connecticut
– -$50K -1,894 Closed
U
114
UBS
Switzerland
– -$42K -1,598 Closed
BJ
115
BlackRock Japan
Japan
– -$28K -1,080 Closed
GSC
116
Ground Swell Capital
South Carolina
– -$3K -100 Closed
TRCT
117
Tower Research Capital (TRC)
New York
– -$1K -37 Closed
1 2 3 4
5

PTCT Hedge Fund Activity: Q3 2014 in Review

99 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2014, worth a combined $1.07B — up 78% from $601M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PTCT positions and 18 closed out — a net gain of 15 holders — while 23 added to existing stakes and 26 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $25.6M. The largest seller was Credit Suisse, cutting an estimated $22.2M.

  • 99 institutional investors held PTC Therapeutics (PTCT) as of Q3 2014, up from 84 in Q2 2014.
  • Funds reported $1.07B of PTC Therapeutics stock for Q3 2014, up 78% quarter-over-quarter.
  • 33 funds opened new PTC Therapeutics positions in Q3 2014 and 18 closed out, a net change of +15 holders.
  • The largest PTC Therapeutics buyer in Q3 2014 was Wellington Management Group, an estimated $25.6M added.
  • The largest PTC Therapeutics seller in Q3 2014 was Credit Suisse, an estimated $22.2M sold.

Based on aggregated 13F filings for Q3 2014.